Compare BioNTech SE - ADR (BNTX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs T Rowe Price Group Inc — how do they compare? BioNTech SE - ADR trades at $91.88 (market cap $22.86B), while T Rowe Price Group Inc trades at $118 (market cap $24.87B). The key difference: BioNTech SE - ADR and T Rowe Price Group Inc are close in size by market cap, and T Rowe Price Group Inc pays a 4.48% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TROW | |
|---|---|---|
Market Cap | $22.86B | $24.87B |
Sector | Health | Financials |
52-Week High | $119.34 | $120.16 |
52-Week Low | $83.89 | $86.19 |
Enterprise Value | $6.53B | $21.58B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
T. Rowe Price (TROW) trades at $113.65, down 4.13% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported June 2026 AUM of $1.89 trillion (PRNewsWire, 2026-07-13), showing steady growth. Recent earnings beat expectations in Q1 2026 with EPS of $2.52 versus $2.33 forecast. Valuation ratios remain attractive with a P/E of 12.19 and ROE of 19.31%, supported by strong cash flow trends.
TROW presents a mixed outlook: analyst consensus is cautious with 63% hold ratings and a $109.17 price target below current levels, but fundamentals like rising net cash flow to $909M in 2026 and a 28.28% net margin offer stability. Key risks include equity outflows and market volatility, while the dividend yield near 4.9% (Investors Business Daily, 2026-06-10) provides income appeal. Upside depends on sustained AUM growth and execution against competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
